Peptide therapy · waitlist open
Peptide care, done the legitimate way.
Clinician-led. Lab-informed. Dispensed by a named US 503A pharmacy with its license number on the label — the honest alternative to the research-chemical vials sold online. We're building it carefully and we'll tell you plainly what the science does and doesn't show. Join the waitlist to hear when it's live.
Start here
You’ve already taken one.
Insulin is a peptide. So is semaglutide — the active ingredient in Ozempic and Wegovy, and in the compounded GLP-1 we prescribe today. A peptide is just a short chain of amino acids, the same building blocks your body uses to make proteins. Your body makes them constantly, to signal hormones, regulate metabolism, and modulate your immune response.
What’s new isn’t the science of peptides. It’s that a specific group of them may soon be legal for US pharmacies to compound again — and that the demand has raced far ahead of anyone offering them responsibly.
What we’re building
Peptides, by what you’re after.
We’re evaluating the full category — but leading with the compounds closest to what a clinician can justify, and honest about where each one actually stands.
Metabolic & weight
MOTS-C
A mitochondrial-derived peptide the FDA reviewed for obesity and osteoporosis — the closest fit to what Form already does. This is where a clinician-reviewed peptide makes the most sense first.
Recovery & repair
BPC-157 · TB-500 · KPV
The peptides people reach for after an injury or for gut and joint recovery. Popular, and among those the FDA is actively re-evaluating for compounding.
Energy & longevity
Metabolic & cellular support
The longevity and cellular-health corner of the category. We are evaluating what a clinician can responsibly stand behind here — and being upfront about how much is still early.
Brain, sleep & mood
Cognitive & restorative
Nootropic and sleep-supportive peptides get a lot of attention online. Some are on the FDA’s current review docket; the Western clinical literature is thin. We treat them accordingly.
Immune support
Immune-modulating
Immune-modulating peptides round out the category. As with the rest, we will only offer what a clinician can justify for a specific patient, sourced from a named pharmacy.
Already lose weight with us? Metabolic peptides like MOTS-C are the natural next conversation with your clinician.
Start with our live GLP-1 program →The honest part
Where the evidence actually stands.
Plenty of sites will tell you peptides are miracle molecules. Here’s the real picture for the four we’re closest to offering. If it reads as underwhelming — good. That’s why we’re not selling them yet.
| Peptide | Studied for | The evidence today |
|---|---|---|
| MOTS-C | Obesity, osteoporosis (the uses FDA reviewed) | Mitochondrial-derived. Metabolic research is genuinely interesting; human data is limited. |
| BPC-157 | Tissue repair, gut and joint recovery | Mostly rodent studies. A 2025 review in the Orthopaedic Journal of Sports Medicine found only a few small human pilot studies. |
| TB-500 | Wound healing, recovery | Even less human data behind it than BPC-157. |
| KPV | Wound healing, inflammation | Limited human data; mechanistically plausible, early clinically. |
The part almost nobody mentions
“Legal” isn’t the same as “available.”
Most of the raw material for these peptides currently exists only in “research use only” grade — not pharmaceutical grade.
Turning an RUO peptide into injectable, pharmaceutical-grade material is estimated to take 18–30 months and requires analytical validation, sterility and stability testing, and an FDA Drug Master File.
So when someone offers you a compounded peptide today, the real question isn’t only “is this allowed?” It’s “where did the active ingredient come from, and what grade is it?” We won’t dispense anything we can’t answer that for.
What you’re probably being offered instead
LegitScript documented a 678% increase in ads for problematic peptides between 2022 and 2024. Demand outran compliant supply — and the gap is being filled by overseas suppliers, “research use only” vials, and sellers with no clinician, no pharmacy license, and no one to call if something goes wrong.
You can’t verify what’s in those vials. That’s the alternative we’re building against — not other clinics.
Our bar
What has to be true before we offer this.
Pharmaceutical-grade API — verified, not “research use only”
We confirm the active ingredient is pharmaceutical grade, not RUO material relabeled for humans.
A named 503A pharmacy on the label
The pharmacy name and license number appear on every shipment. No anonymous “partner network.”
Category-1 standing, monitored continuously
A one-time check isn’t enough. Regulatory status is monitored on an ongoing basis before we dispense.
A written clinical protocol
Who qualifies, dosing, monitoring intervals — defined before anyone is prescribed anything.
Informed consent that states the evidence honestly
For compounds with thin human data, the consent says exactly what is and isn’t known.
A clinician who can say no
If a compounded peptide isn’t justified for you, we decline and refer — same as our GLP-1 program.
Where the regulation actually stands
What changed — and what hasn’t.
In February 2026, several peptides (including BPC-157) were moved to FDA Category 1. Important nuance: Category 1 means the FDA intends to exercise enforcement discretion while it evaluates them — that is not FDA approval.
On July 23, 2026, an FDA advisory committee voted — narrowly, and against the FDA staff’s own briefing — to recommend adding BPC-157, KPV, TB-500, and MOTS-C to the formal 503A Bulks List. That recommendation is non-binding, and no final rule has been issued.
Licensed clinics already prescribe some of these on the Category-1 basis. We’re building to do the same — carefully, with the sourcing and clinical bar above — rather than waiting indefinitely, and rather than rushing.
Longer reads: the 503A legal picture, MOTS-C and metabolic health, and what changed in 2026.
Waitlist
Be first when it’s live.
Tell us which direction interests you. When a clinician-reviewed peptide option opens, waitlist members hear first — with the evidence, the pharmacy, and the price stated plainly.
Looking for our live program? Compounded GLP-1 for weight management is available today. Start the 60-second eligibility check →
Interested in (optional)
Compounded peptides are prepared under section 503A of the FD&C Act and are not FDA-approved as finished products. Availability depends on evolving FDA regulation and clinician judgment.
No doctor-patient relationship is formed by completing the eligibility quiz on this website. Form Healthtech Innovations LLC is a software platform, not a medical practice or pharmacy. Prescriptions are issued only after an online evaluation by an independent licensed clinician contracted through our medical group partner. Compounded medications are dispensed by state-licensed 503A pharmacies and are not FDA-approved as finished products.
Form is pre-launch and has not yet published its own patient-outcome data. Any efficacy figures for the drug class (for example, clinical-trial results for FDA-approved branded GLP-1 medications) refer to those branded products, not to compounded formulations, which have not been studied as finished products. When Form has its own results, we will publish them with the sample size and methodology attached. Individual results vary and depend on clinical appropriateness, adherence, and your clinician’s recommendations.